Rituximab

About

Therapy type: Immunotherapy

Therapy strategy: CD20 inhibition

Mappings

NCI Thesaurus: Rituximab (ncit:C1702)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) HC (1) CD20 + Non-Hodgkin Lymphoma Rituximab
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
FDA (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Burkitt Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Mature B-Cell Neoplasms Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Chronic Lymphocytic Leukemia Cyclophosphamide, Fludarabine, Rituximab
HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
HC (1) CD20 + Follicular Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
HC (1) CD20 + Follicular Lymphoma Rituximab